We are a London-based biopharmaceutical company using our expertise of opioid antagonists to develop modern addiction treatments. Right now, our focus is on completing the clinical trials of an opioid antagonist-based nasal spray for the treatment of Binge Eating Disorder, which is the……        Learn more about our products in development. Binge Eating Disorder Treatment Bulimia Nervosa Treatment Prospective Treatments   LLTP to Develop Opioid Drug Treatment in Collaboration with the National Institute on Drug Abuse (NIDA) LLTP Provides Guidance on Company Operations LLTP Presents Clinical Trial Results to APA LLTP Appoints Kevin Pollack New CFO LLTP Appoints Dr. David Kessler as Strategic Advisor LLTP Announces Positive Preliminary Phase II Clinical Trial Results of Binge Eating Disorder Treatment LLTP Appoints Pollack to Board LLTP Responds to Questions About Trading LLTP Applies Patented Technology to New Treatment for PMS Overeating LLTP Discusses New Opiate Overdose Treatment with King's College, London LLTP to Conduct Phase II Testing of New Bulimia Nervosa Treatment at King’s College, London LLTP Set to Begin Phase II Clinical Trials of Binge Eating Disorder Treatment LLTP Takes Safer Approach to Obesity